New York, New York--(Newsfile Corp. - August 14, 2026) - Kaplan Fox &amp; Kilsheimer LLP is investigating potential securities violations against Hims &amp; Hers Health, Inc. (&#34;Hims &amp; Hers&#34; or the

<p>New York, New York--(Newsfile Corp. - August 14, 2026) - <a href="https://api.newsfilecorp.com/redirect/DOPLDtnD0r">Kaplan Fox &#38; Kilsheimer LLP</a> is investigating potential securities violations against Hims &#38; Hers Health, Inc. ("Hims &#38; Hers" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/HIMS">HIMS</a>).</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/rpQa8Iqkbk">CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION</a></p><p><b>If you are a Hims &#38; Hers investor and have suffered losses, or if you have information that could assist in the Hims &#38; Hers investigation, you may </b><a href="https://api.newsfilecorp.com/redirect/VvGyDTYkGa"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:pmayer@kaplanfox.com"><b>pmayer@kaplanfox.com</b></a><b> or by calling (646) 315-9003.</b></p><p>On July 29, 2026, the Federal Trade Commission ("FTC"), the People of the State of California through Los Angeles County Counsel and the Utah Division of Consumer Protection sued Hims &#38; Hers in the Northern District of California. According to the FTC, the action alleges that Hims &#38; Hers fails to clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them." The FTC also alleges that the company has made it difficult for consumers to cancel subscriptions and misled consumers about keeping their health information private. The FTC alleges that Hims shared consumers' health information with Meta, Snap and other third parties.</p><p>Following this news, the price of Hims &#38; Hers stock fell $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026.</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America</i>-the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act-$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.</p><p>If you have any questions about this investigation, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b></p><p>Pamela A. Mayer<br /><a href="https://api.newsfilecorp.com/redirect/zAPajiyY1M">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(646) 315-9003<br /><a href="mailto:pmayer@kaplanfox.com">pmayer@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/4YrN7HWLAX">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/jNraoIrmXp">https://www.kaplanfox.com/case/hims-hers-health-inc-class-action-investigation-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/309100_4f0b62fd84893b61_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/vE5a8hDZGB">https://www.newsfilecorp.com/release/309100</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/309100/197" alt="" /></p>

HIMS

Kaplan Fox & Kilsheimer LLP Announces an Investigation into Hims & Hers Health, Inc. (HIMS) for Possible Securities Law Violations

FTC and states sue Hims & Hers; stock drops amid investigation

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>New York, New York--(Newsfile Corp. - August 14, 2026) - Kaplan Fox &amp;amp; Kilsheimer LLP is investigating potential securities violations against Hims &amp;amp; Hers Health, Inc. (&amp;#34;Hims &amp;amp; Hers&amp;#34; or the</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Regulators allege Hims &amp; Hers misled about prescription charges and privacy practices, while restricting cancellation. The FTC, California, and Utah sue in the Northern District of California; Kaplan Fox has launched its own securities investigation. The stock fell about 14.7% on July 29, 2026, signaling investor concern and potential additional disclosures or settlements.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>FTC and California/Utah actions allege Hims misled on prescription charges. Privacy concerns cited.</li><li>Stock dropped 14.73% to $25.00 on July 29, 2026.</li><li>Kaplan Fox &amp; Kilsheimer LLP launched the securities investigation.</li><li>FTC alleges data sharing with Meta and Snap; broader privacy scrutiny.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Hims &amp; Hers Health, Inc. (HIMS)</strong>: Subject of the FTC/state actions; regulatory risk and potential penalties could affect operations and disclosures.</li><li><strong>Meta Platforms, Inc. (META)</strong>: FTC alleges data sharing with Meta; privacy concerns could affect platform partnerships and consumer trust.</li><li><strong>Snap Inc. (SNAP)</strong>: Alleged data sharing; potential scrutiny and reputational impact for ad/health data partners.</li><li><strong>Kaplan Fox &amp; Kilsheimer LLP (N/A)</strong>: Plaintiffs&#039; firm launching securities investigation; not a market participant but could influence investor perceptions.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>This is a legal/regulatory development affecting a consumer-health company; it could influence risk, valuation, and future disclosures.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Regulatory actions raise material regulatory and litigation risk for HIMS.</li><li>Data-privacy allegations involving Meta and Snap could trigger additional scrutiny.</li><li>Recent 14.7% stock drop signals elevated near-term downside risk.</li><li>Possible settlements or consent orders could alter cash flows and disclosures.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>FTC, CA via LA County Counsel, and Utah DPP sued Hims &amp; Hers on July 29, 2026.</li><li>Hims stock closed at $25.00 on July 29, 2026, down $4.32 (14.73%).</li><li>FTC alleges improper disclosure of prescription charges and difficulty canceling subscriptions.</li><li>FTC alleges sharing health data with Meta, Snap and other third parties.</li><li>Kaplan Fox &amp; Kilsheimer LLP announced investigation seeking information from investors.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bearish near-term on regulatory risk; monitor settlement, disclosure changes, or penalties within 3-6 months.</p>
  </section>
</section>


<p>New York, New York--(Newsfile Corp. - August 14, 2026) - <a href="https://api.newsfilecorp.com/redirect/DOPLDtnD0r">Kaplan Fox &#38; Kilsheimer LLP</a> is investigating potential securities violations against Hims &#38; Hers Health, Inc. ("Hims &#38; Hers" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/HIMS">HIMS</a>).</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/rpQa8Iqkbk">CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION</a></p><p><b>If you are a Hims &#38; Hers investor and have suffered losses, or if you have information that could assist in the Hims &#38; Hers investigation, you may </b><a href="https://api.newsfilecorp.com/redirect/VvGyDTYkGa"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:pmayer@kaplanfox.com"><b>pmayer@kaplanfox.com</b></a><b> or by calling (646) 315-9003.</b></p><p>On July 29, 2026, the Federal Trade Commission ("FTC"), the People of the State of California through Los Angeles County Counsel and the Utah Division of Consumer Protection sued Hims &#38; Hers in the Northern District of California. According to the FTC, the action alleges that Hims &#38; Hers fails to clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them." The FTC also alleges that the company has made it difficult for consumers to cancel subscriptions and misled consumers about keeping their health information private. The FTC alleges that Hims shared consumers' health information with Meta, Snap and other third parties.</p><p>Following this news, the price of Hims &#38; Hers stock fell $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026.</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America</i>-the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act-$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.</p><p>If you have any questions about this investigation, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b></p><p>Pamela A. Mayer<br /><a href="https://api.newsfilecorp.com/redirect/zAPajiyY1M">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(646) 315-9003<br /><a href="mailto:pmayer@kaplanfox.com">pmayer@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/4YrN7HWLAX">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/jNraoIrmXp">https://www.kaplanfox.com/case/hims-hers-health-inc-class-action-investigation-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/309100_4f0b62fd84893b61_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/vE5a8hDZGB">https://www.newsfilecorp.com/release/309100</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/309100/197" alt="" /></p>

Regulators allege Hims & Hers misled about prescription charges and privacy practices, while restricting cancellation. The FTC, California, and Utah sue in the Northern District of California; Kaplan Fox has launched its own securities investigation. The stock fell about 14.7% on July 29, 2026, signaling investor concern and potential additional disclosures or settlements.

News insight

Kaplan Fox & Kilsheimer LLP Announces an Investigation into Hims & Hers Health, Inc. (HIMS) for Possible Securities Law Violations

AI summary

Sentiment rationale

Key facts

Legal